INSIDE INFORMATION REGULATED INFORMATION
Nyxoah Raises $27 Million through its At-the-Market Offering
Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus
Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company has sold 3.0 million shares raising $27.0 million in gross proceeds pursuant to the Company’s $50 million at-the-market (“ATM”) offering at a price per share equal to the market price on the Nasdaq Global Market at the time of sale. The shares were sold, based on interest received, to a single U.S.-based healthcare investor.
This investment marks a significant milestone for Nyxoah as it not only strengthens the Company’s balance sheet but also reinforces its focus on the U.S. market. With the new influx of funds, Nyxoah will be able to further develop its innovative treatment options for OSA and potentially expand its reach to more patients in need.
The confidence shown by the new U.S.-based healthcare investor reflects the growing interest and recognition of Nyxoah’s groundbreaking technology in the medical community. This strategic partnership is expected to drive growth and propel Nyxoah to new heights in the field of neuromodulation for OSA treatment.
Overall, this development signals a promising future for Nyxoah and the patients suffering from OSA, as the Company continues to innovate and advance its mission of providing effective and accessible treatment options for this prevalent sleep disorder.
How this will affect me:
As a potential patient suffering from Obstructive Sleep Apnea, this investment by a new U.S.-based healthcare investor in Nyxoah could lead to the development of more advanced and effective treatment options for OSA. This could potentially improve my quality of life and provide me with better alternatives for managing this sleep disorder.
How this will affect the world:
The advancements made by Nyxoah in the field of neuromodulation for OSA treatment have the potential to impact the world by offering innovative solutions for a common yet often overlooked sleep disorder. This investment signifies a step forward in improving global access to effective OSA therapy and enhancing overall healthcare outcomes for patients worldwide.
Conclusion:
In conclusion, Nyxoah’s successful raise of $27 million through its at-the-market offering not only strengthens the Company’s financial position but also solidifies its commitment to advancing treatment options for Obstructive Sleep Apnea. With the support of a new U.S.-based healthcare investor, Nyxoah is poised to make significant strides in the field of neuromodulation and bring hope to patients suffering from this pervasive sleep disorder.
